Ariela Katz | Authors


Immunoscore Provides Risk Assessments for All Stages of Colon Cancer

November 13, 2018

In a presentation at the 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cance, Dr. Galon discussed the definition of the immune contexture of Immunoscore, its international validation for the risk-classification of stage I-III colon cancer, and the potential value of Immunoscore in stage IV metastatic disease.

Rucaparib Granted Breakthrough Designation by FDA for mCRPC

October 02, 2018

Rucaparib (Rubraca) has received a breakthrough therapy designation from the FDA for single-agent use in adult patients with BRCA1/2-positive metastatic castration-resistant prostate cancer following at least 1 androgen receptor–directed therapy and taxane-based chemotherapy.

Choosing Between Docetaxel or Abiraterone With ADT in Hormone-Sensitive Prostate Cancer

May 18, 2018

Findings from the CHAARTED, LATITUDE, and STAMPEDE trials showed various results for adding docetaxel or abiraterone acetate to androgen deprivation therapy in prostate cancer, and this kicked off a challenging issue for clinicians: Is it better to add docetaxel, abiraterone acetate, both, or neither to their patient’s treatment plan?

DNA Repair Deflects Strong Targets for Prostate Cancer Therapy

May 16, 2018

Patients with prostate cancer and DNA damage repair defects could be candidates for therapy involving poly polymerase inhibitors, and there is strong justification for activating clinical trials in this space, according to Maha Hussain, MD, the Genevieve Teuton Professor of Medicine and deputy director of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.